Premium
Cannabidiol trial for schizophrenia shows no effect on cognition, symptoms
Publication year - 2018
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30358
Subject(s) - cannabidiol , schizophrenia (object oriented programming) , adjunctive treatment , psychopharmacology , mood , placebo , medicine , cognition , psychiatry , antipsychotic , cannabinoid , psychology , cannabis , alternative medicine , receptor , pathology
Antipsychotic‐treated patients with schizophrenia who received cannabidiol 600 mg/day as adjunctive treatment saw no improvement in cognition or symptoms of schizophrenia in a placebo‐controlled trial. The study, results of which were published online April 5 in Psychopharmacology , found that the cannabinoid was well‐tolerated, with no major effects on mood or movement.